Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients

  • P. Reimer
  • M. K. Virarkar
  • M. Binnenhei
  • M. Justinger
  • M. R. Schön
  • K. Tatsch
Clinical Investigation

Abstract

Introduction

To investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE) therapy.

Materials and Methods

Between 2005 and 2016, 21 patients with ICC were treated with Y-90 RE only and their survival data were analyzed. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Result

The overall median survival was 15 months. Survival was significantly (p = 0.009) prolonged in patients with tumor burden of ≤ 25% (n = 8, OS 37.5 months) versus those with a tumor burden of 25–50% (n = 13, OS 15 months). The other variables: tumor morphology (infiltrative vs. peripheral), tumor distribution (solitary vs. multifocal), lobes involved (unilobar vs. bilobar), FDG PET status (FDG avid vs. non-avid), RE treatment sessions (1 session vs. 2 sessions), metastases (metastasis vs. no metastasis) and RECIST criteria, had no significant impact on survival.

Conclusion

Tumor burden represents a key prognostic factor of survival in therapy-naïve patients with unresectable ICC treated with Y-90 RE therapy only.

Keywords

Overall survival Yttrium-90 radioembolization Intrahepatic cholangiocarcinoma Tumor burden 

Notes

Acknowledgements

We are indebted to Dr. D. H. Wollschlaeger and Dr. F. Barakat for their helpful comments in data acquisition.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

References

  1. 1.
    Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48(1):308–21.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Shaib YH, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Seidensticker R, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35(5):1066–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Sangro B, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.CrossRefPubMedGoogle Scholar
  6. 6.
    Bridgewater J, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoffmann RT, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Mosconi C, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115(3):297–302.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lee EW, et al. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: current and Updated Literature Review. Korean J Radiol. 2016;17(4):472–88.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kennedy A, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Kucuk ON, et al. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. World J Surg Oncol. 2011;9:86.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Cirillo M, et al. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol. 2009;20(12):1929–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Tirkes T, et al. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33(5):1323–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  15. 15.
    Boehm LM, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Seidensticker R, Ricke J, Seidensticker M. Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):319–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ibrahim SM, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–28.CrossRefPubMedGoogle Scholar
  19. 19.
    Camacho JC, et al. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.CrossRefPubMedGoogle Scholar
  20. 20.
    Filippi L, et al. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42(1):59–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Rafi S, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Saxena A, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–91.CrossRefPubMedGoogle Scholar
  23. 23.
    Soydal C, et al. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med. 2016;30(1):29–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Kiefer MV, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498–505.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim JH, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113(7):1614–22.CrossRefPubMedGoogle Scholar
  26. 26.
    Vogl TJ, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012;131(3):733–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Aliberti C, et al. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31(5):883–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Burger I, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16(3):353–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Herber S, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2007;30(6):1156–65.CrossRefPubMedGoogle Scholar
  30. 30.
    Park SY, et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011;66(4):322–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Kuhlmann JB, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43.PubMedGoogle Scholar
  32. 32.
    Beuzit L, et al. Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85(8):1445–52.CrossRefPubMedGoogle Scholar
  33. 33.
    Rayar M, et al. Multimodal Therapy including Yttrium-90 Radioembolization as a Bridging Therapy to Liver Transplantation for a Huge and Locally Advanced Intrahepatic Cholangiocarcinoma. J Gastrointestin Liver Dis. 2016;25(3):401–4.PubMedGoogle Scholar
  34. 34.
    Haug AR, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38(6):1037–45.CrossRefPubMedGoogle Scholar
  35. 35.
    Sangro B, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–46.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  1. 1.Institute for Diagnostic and Interventional RadiologyKlinikum Karlsruhe, Academic Teaching Hospital of the University of FreiburgKarlsruheGermany
  2. 2.Department of Diagnostic RadiologyM D Anderson Cancer CenterHoustonUSA
  3. 3.Medical Clinic III, Department of Hematology, Oncology, Infectious Disease and Palliative MedicineKlinikum Karlsruhe, Academic Teaching Hospital of the University of FreiburgKarlsruheGermany
  4. 4.Department of General and Visceral SurgeryKlinikum Karlsruhe, Academic Teaching Hospital of the University of FreiburgKarlsruheGermany
  5. 5.Department of Nuclear MedicineKlinikum Karlsruhe, Academic Teaching Hospital of the University of FreiburgKarlsruheGermany

Personalised recommendations